Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA)

References

• Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Rockville (MD): Center for Behavioral Health Statistics and Quality; 2020.
   Google Scholar
• CDC. Overdose deaths accelerating during COVID-19. Atlanta (GA): CDC; 2020.
   Google Scholar
• CDC. Drug overdose deaths in the U.S. top 100,000 annually. Atlanta (GA): CDC; 2021.
   Google Scholar
• Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):1–9.
   PubMed Web of Science ®Google Scholar
• Minnesota Department of Health. Nonfatal drug overdoses increased during COVID-19 pandemic. 2021. Available at: https://www.health.state.mn.us/news/pressrel/2021/overdose093021.html
   Google Scholar
• Zibbell JH, Clark SD, Ferrell A, et al. Non-fatal opioid overdose and associated health outcomes: final summary report. 2019. RTI International. Available at: https://aspe.hhs.gov/reports/non-fatal-opioid-overdose-associated-health-outcomes-final-summary-report-0
   Google Scholar
• Degenhardt L, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560–1579.
   PubMed Web of Science ®Google Scholar
• Warner-Smith M, et al. Heroin overdose: causes and consequences. Addiction. 2001;96(8):1113–1125.
   PubMed Web of Science ®Google Scholar
• Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone–Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443–444.
   PubMed Web of Science ®Google Scholar
• Havens JR, Walker R, Leukefeld CG. Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users. Drug Alcohol Depend. 2007;87(1):98–102.
   PubMed Web of Science ®Google Scholar
• White RH, O’Rourke A, Kilkenny ME, et al. Prevalence and correlates of receptive syringe-sharing among people who inject drugs in rural Appalachia. Addiction. 2021;116(2):328–336.
   PubMed Web of Science ®Google Scholar
• Schneider KE, White RH, Musci RJ, et al. The relationship between polysubstance injection drug use, HIV risk behaviors, and interest in pre-exposure prophylaxis (PrEP) among people who inject drugs in rural West Virginia. J Stud Alcohol Drugs. 2020;81(6):740–749.
   PubMed Web of Science ®Google Scholar
• CDC. HIV and substance use. 2021. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/hiv/basics/hiv-transmission/injection-drug-use.html
   Google Scholar
• Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171, iii–iv.
   PubMed Web of Science ®Google Scholar
• Gowing L, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;(2):Cd004145.
   PubMed Web of Science ®Google Scholar
• Gowing LR, Farrell M, Bornemann R, et al. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21(2):193–195.
   PubMed Web of Science ®Google Scholar
• Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30(2):155–166.
   PubMed Web of Science ®Google Scholar
• Cernasev A, Hohmeier KC, Frederick K, et al. A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Explor Res Clin Soc Pharm. 2021;2:100029.
   PubMedGoogle Scholar
• Abraham AJ, Andrews CM, Harris SJ, et al. Coverage and prior authorization policies for medications for opioid use disorder in medicaid managed care. JAMA Health Forum. 2022;3(11):e224001.
   PubMedGoogle Scholar
• Cioe K, Biondi BE, Easly R, et al. A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:108146.
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315–326.
   PubMed Web of Science ®Google Scholar
• Lin LA, Lofwall MR, Walsh SL, et al. Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug Alcohol Depend. 2018;186:147–153.
   PubMed Web of Science ®Google Scholar
• Sohler NL, Weiss L, Egan JE, et al. Consumer attitudes about opioid addiction treatment: a focus group study in New York city. J Opioid Manag. 2013;9(2):111–119.
   PubMedGoogle Scholar
• Peterson JA, Schwartz RP, Mitchell SG, et al. Why don’t out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy. 2010;21(1):36–42.
   PubMed Web of Science ®Google Scholar
• Morral AR, Belding MA, Iguchi MY. Identifying methadone maintenance clients at risk for poor treatment response: pretreatment and early progress indicators. Drug Alcohol Depend. 1999;55(1–2):25–33.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;2009(3):Cd002209.
   PubMedGoogle Scholar
• Fairbairn N, Ross J, Trew M, et al. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline. CMAJ. 2019;191(38):E1049–E1056.
   PubMed Web of Science ®Google Scholar
• Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
   PubMed Web of Science ®Google Scholar
• Meyer M, Eichenberger R, Strasser J, et al. «One prick and then it’s done»: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. Harm Reduct J. 2021;18(1):134.
   PubMed Web of Science ®Google Scholar
• Meyer M, Strasser J, Köck P, et al. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic–is an update of legal restrictions warranted? Int J Drug Policy. 2022;101:103548.
   PubMed Web of Science ®Google Scholar
• F. Martins ML, Wilthagen EA, Oviedo-Joekes E, et al. The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: a scoping review. Drug Alcohol Depend. 2021;227:108984.
   PubMed Web of Science ®Google Scholar
• Liebrenz M, Gamma A, Buadze A, et al. Fifteen years of heroin-assisted treatment in a Swiss prison—a retrospective cohort study. Harm Reduct J. 2020;17(1):67.
   PubMed Web of Science ®Google Scholar
• Blanken P, Hendriks VM, van Ree JM, et al. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in The Netherlands. Addiction. 2010;105(2):300–308.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, March JC, Romero M, et al. The Andalusian trial on heroin-assisted treatment: a 2 year follow-up. Drug Alcohol Rev. 2010;29(1):75–80.
   PubMed Web of Science ®Google Scholar
• Verthein U, Bonorden-Kleij K, Degkwitz P, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960–966. discussion 967–8.
   PubMed Web of Science ®Google Scholar
• Smart R, Reuter P. Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials. Addiction. 2022;117(3):518–531.
   PubMed Web of Science ®Google Scholar
• Uchtenhagen A. The role and function of heroin assisted treatment at the treatment system level. Heroin Addict Relat Clin Prob. 2017;19(2):17–24.
   Web of Science ®Google Scholar
• Farrell M, Hall W. Heroin-assisted treatment: has a controversial treatment come of age?†. Br J Psychiatry. 2015;207(1):3–4.
   PubMed Web of Science ®Google Scholar
• Strang J, Groshkova T, Uchtenhagen A, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction†. Br J Psychiatry. 2015;207(1):5–14.
   PubMed Web of Science ®Google Scholar
• Alliance DP. Heroin-assisted treatment. 2023. Drug Policy Alliance. Available at: https://drugpolicy.org/issues/HAT
   Google Scholar
• Nordt C, Vogel M, Dey M, et al. One size does not fit all-evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114(1):103–111.
   PubMed Web of Science ®Google Scholar
• Kilmer B, Taylor J, Caulkins JP, et al. Considering heroin-assisted treatment and supervised drug consumption sites in the United States. 2018. Santa Monica (CA): RAND Corporation.
   Google Scholar
• Rehm J, Gschwend P, Steffen T et al. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001;358(9291):1417–1423.
   PubMed Web of Science ®Google Scholar
• van den Brink W, Hendriks VM, Blanken P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003;327(7410):310.
   PubMed Web of Science ®Google Scholar
• Oviedo-Joekes E, Brissette S, Marsh DC, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009;361(8):777–786.
   PubMed Web of Science ®Google Scholar
• March JC, Oviedo-Joekes E, Perea-Milla E, et al. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat. 2006;31(2):203–211.
   PubMed Web of Science ®Google Scholar
• Smart R. Evidence on the effectiveness of heroin-assisted treatment. 2018. RAND Corporation. Available at: https://www.rand.org/pubs/working_papers/WR1263.html
   Google Scholar
• Substance Abuse and Mental Health Services Administration (SAMHSA). MAT medications, counseling, and related conditions. 2023. https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/buprenorphine
   Google Scholar
• Tomko C, Schneider KE, Rouhani S, et al. Identifying pathways to recent non-fatal overdose among people who use opioids non-medically: how do psychological pain and unmet mental health need contribute to overdose risk? Addict Behav. 2022;127:107215.
   PubMed Web of Science ®Google Scholar
• Rouhani S, Schneider KE, Rao A, et al. Perceived vulnerability to overdose-related arrests among people who use drugs in Maryland. Int J Drug Policy. 2021;98:103426.
   PubMed Web of Science ®Google Scholar
• Schneider KE, Urquhart GJ, Rouhani S, et al. Practical implications of naloxone knowledge among suburban people who use opioids. Harm Reduct J. 2021;18(1):47.
   PubMed Web of Science ®Google Scholar
• Allen ST, Footer KHA, Galai N, et al. Implementing targeted sampling: lessons learned from recruiting female sex workers in Baltimore, MD. J Urban Health. 2019;96(3):442–451.
   PubMed Web of Science ®Google Scholar
• Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. BMC Med Res Method. 2008;8(1):9.
   PubMedGoogle Scholar
• Xu KY, Mintz CM, Presnall N, et al. Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use. JAMA Netw Open. 2022;5(5):e2211363.
   PubMed Web of Science ®Google Scholar
• Elliott L, Bennett AS, Wolfson-Stofko B. Life after opioid-involved overdose: survivor narratives and their implications for ER/ED interventions. Addiction. 2019;114(8):1379–1386.
   PubMed Web of Science ®Google Scholar
• Pollini RA, McCall L, Mehta SH, et al. Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend. 2006;83(2):104–110.
   PubMed Web of Science ®Google Scholar